- Candoxatril
-
- $293.00 / 1mg
-
2025-11-10
- CAS:123122-55-4
- Min. Order:
- Purity: 98.90%
- Supply Ability: 10g
- Candoxatril
-
- $293.00 / 1mg
-
2025-11-10
- CAS:123122-55-4
- Min. Order:
- Purity: 98.90%
- Supply Ability: 10g
|
| | CANDOXATRIL Basic information |
| Product Name: | CANDOXATRIL | | Synonyms: | 4α-[[1-[(S)-2-(Indan-5-yloxycarbonyl)-3-(2-methoxyethoxy)propyl]cyclopentan-1-yl]carbonylamino]cyclohexane-1α-carboxylic acid;UK-79300;Candoxatril [usan:inn:ban];candoxatril;cis-4-[[[1-[(2S)-3-[(2,3-Dihydro-1H-inden-5-yl)oxy]-2-[(2-Methoxyethoxy)Methyl]-3-oxopropyl]cyclopentyl]carbonyl]aMino]cyclohexanecarboxylic Acid;Cyclohexanecarboxylic acid, 4-[[[1-[(2S)-3-[(2,3-dihydro-1H-inden-5-yl)oxy]-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl]carbonyl]amino]-,cis-;Candoxatril
(UK 79300);(1r,4s)-4-(1-((s)-3-((2,3-dihydro-1h-inden-5-yl)oxy)-2-((2-methoxyethoxy)methyl)-3-oxopropyl)cyclopentane-1-carboxamido)cyclohexane-1-carboxylic acid | | CAS: | 123122-55-4 | | MF: | C29H41NO7 | | MW: | 515.63834 | | EINECS: | | | Product Categories: | Aromatics;Chiral Reagents;Pharmaceuticals;Inhibitors;Intermediates & Fine Chemicals | | Mol File: | 123122-55-4.mol |  |
| | CANDOXATRIL Chemical Properties |
| Melting point | 107-109° | | alpha | D -5.8° (c = 1 in methanol) | | Boiling point | 718.4±60.0 °C(Predicted) | | density | 1.21±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 4.84±0.25(Predicted) | | form | Solid | | color | White to off-white |
| | CANDOXATRIL Usage And Synthesis |
| Uses | Neutral endopeptidase inhibitor. Used in treatment of congestive heart failure. | | Uses | Neutral endopeptidase inhibitor. Candoxatril is used in treatment of congestive heart failure. | | Definition | ChEBI: The 2,3-dihydro-1H-inden-5-yl ester of the active enantiomer of candoxatrilat. Candoxatril is an orally active prodrug of candoxatrilat, a potent neutral endopeptidase (NEP, neprilysin) inhibitor used in the treatment of chronic heart fa
lure. | | in vivo | While the NEP inhibitors have no significant effect on body weight, food and water intake, mean blood pressure or creatinine levels, they do increase cGMP levels in the urine and affected hematopoiesis in an anti-inflammatory way. Moreover, a-SMA deposition in the kidney cortex is inversely correlated with cGMP elevation suggesting a NEP dependent antifibroti effect. High quality mRNA profiles are obtained with at least 8 independent samples per treatment group. The data confirms the cGMP dependent anti-fibrotic action of Sol-1 and further supports the potential therapeutic actions of this neutral endopeptidase inhibitor[2]. |
| | CANDOXATRIL Preparation Products And Raw materials |
|